Strategic Acquisition Opportunity: VintaBio's Viral Vector Manufacturing Facility, Specialized Equipment and Proprietary Technology Assets Available for Bids

PHILADELPHIA--(BUSINESS WIRE)--The Assignee of VintaBio, Inc., a leader in advanced viral vector and vaccine manufacturing, is inviting bids for the company's assets, including a purpose-built cGMP facility, specialized bioprocessing equipment, and related intellectual property and proprietary manufacturing know-how. Following VintaBio's Assignment for the Benefit of Creditors on October 27, 2026, the Assignee is seeking competitive offers for these specialized biotechnology manufacturing assets.

VintaBio presents a strategic acquisition opportunity combining proprietary viral vector manufacturing technology with established cGMP infrastructure. Its 22,500-square-foot Philadelphia facility, representing approximately $17 million in capital investment, includes three cGMP suites, fill-and-finish capabilities, and supporting laboratories.

VintaBio's fixed-bed bioreactor platform is designed for high-yield, high-purity production with improved efficiency and a reduced manufacturing footprint. With demonstrated GMP manufacturing of AAV8 vectors and potential applications across multiple viral vector modalities, the acquisition offers buyers an opportunity to accelerate manufacturing capabilities while reducing development time and capital requirements.

Investment Opportunity:

The assets offer CDMOs, gene therapy developers, vaccine manufacturers, and biotechnology companies an opportunity to expand capacity, vertically integrate production, or acquire differentiated manufacturing capabilities.

Available assets include a purpose-built cGMP facility, specialized bioreactors, purification systems, analytical equipment, and potentially proprietary technologies and know-how, including VintaCells, VintaProcess, and extended-harvest methodologies.

Acquirers may pursue the facility, individual equipment, or available intellectual property and know-how, providing a potentially faster, more capital-efficient path to expanding viral vector and vaccine manufacturing capabilities.

Bid Submission Details:

Interested parties are invited to submit bids for VintaBio's assets by December 15, 2026, at 5:00 PM Eastern Time. A confidentiality and non-disclosure agreement will grant qualified bidders access to a virtual data room for due diligence. The bid process is structured to ensure fairness and transparency, with detailed submission guidelines available upon request.

The Assignee will consider proposals for the facility and installed assets, individual or packaged equipment acquisitions, and potentially related intellectual property and know-how. An in-place facility transaction would be subject to applicable lease terms, landlord consent, and other required approvals.

All inquiries should be directed to representatives of the Assignee, Development Specialists, Inc. For inquiries and further information regarding the bid submission process, please contact Steven L. Victor at [e-mail] or Craig Nurick at [e-mail].

The Assignee is represented by Duane Morris LLP; Christopher M. Winter at [e-mail] or Andrew Lee at [e-mail].

About DSI Assignments:

DSI Assignments specializes in providing experienced assignees to help businesses navigate financial distress. Operating within state laws, our team ensures transparent communication with creditors, manages stakeholder expectations, and negotiates with lenders and investors toward the maximal outcome. Led by Steven L. Victor and Matthew P. Sorenson, recognized experts in restructuring, bankruptcy, and assignments for the benefit of creditors (ABCs), DSI tailors each engagement to the unique needs of the business. ABCs offer an efficient alternative to bankruptcy, and our professionals are dedicated to maximizing value and creditor recoveries for stakeholders.